FDA clears IND application for T-cell receptor therapy to treat epithelial cancers

fda clears ind application for t cell receptor therapy to treat epithelial cancers

Sumary of FDA clears IND application for T-cell receptor therapy to treat epithelial cancers:

  • These include gastrointestinal, lung, cervical and triple-negative breast cancers.
  • “TCR T-cell therapy is a promising new treatment modality that has demonstrated clinical activity in a subset of solid tumors,” Norberg said in a T-Cure-issued press release.
  • “Our hope is that KK-LC-1 TCR-T cell therapy can be effective against common epithelial cancers, which account for 80% to 90% of all human malignancies.
  • “We are excited that NCI has obtained the regulatory approval from FDA to initiate a first-in-human trial against a very important target in multiple solid tumors,” Gang Zeng, PhD, CEO of T-Cure, said in the release.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close